American College of Nuclear Medicine Names Alan Klitzke as 47th President

Alan Klitzke, MD

Alan Klitzke, MD

Alan Klitzke, MD has been named the 2018 president of the American College of Nuclear Medicine (ACNM). He will serve a 1-year term with the goal of advancing the field both nationally and internationally.

ACNM is an international organization composed of physicians and scientists involved in both clinical and scientific practice of nuclear medicine. Klitzke plans to develop a new collaboration agreement between the ACNM and the British Nuclear Medicine Society during his time as president.

Klitzke is an associate professor of oncology in the Department of Diagnostic Radiology at Roswell Park Comprehensive Cancer Center, as well as an assistant professor of radiology and assistant professor of nuclear medicine at the Jacobs School of Medicine and Biomedical Sciences at the University of Buffalo.

He specializes in whole-body PET/CT imaging, CT guided biopsy procedures, CT, MRI, and Ultrasound imaging of the thorax, abdomen, and pelvis. He works closely with a team of doctors to ensure all patients are diagnosed and treated properly at Roswell Park Comprehensive Cancer Center as a diagnostic physician.

Roswell Park Comprehensive Cancer Center is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. It is a community of doctors driven to eliminate cancer by unlocking new discoveries through personalized approaches.

Prior to his installment as the president of ACNM at the annual awards ceremony, Klitzke was recognized for his service in nuclear medicine by the former president. He was 1 of 3 recipients for the President’s Award.

“As the president of ACNM, I will work to continue the advancement of not only this field, but the organization as well,” Klitzke said in a statement. “I am humbled and honored to take on this leadership role. I look forward to what we will accomplish in this year ahead.”

The ACNM can look forward to new advancements in diagnostic and therapeutic medicine and international collaborations under Klitzke’s 1-year term as president.